CompletedPhase 2

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

United States50 participantsStarted 2012-06

Plain-language summary

This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with chronic plaque psoriasis aged 18 to 75 who have had insufficient response to topical agents, and who meet the psoriasis assessment expectations as defined in the study protocol Exclusion Criteria: * Females who are pregnant or breastfeeding * Men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively * Subjects treated with leflunomide or other biological therapies to treat psoriasis and all JAK-STAT inhibitors within 12 weeks prior to first dose of study drug

What they're measuring

Safety and tolerability of itacitinib as measured by changes in frequency and severity of adverse events, ECGs, physical examination, vital signs, and clinical laboratory evaluations.

Timeframe: Approximately two months.

The mean percent change from baseline in static Physician's Global Assessment (sPGA) on the day 28 visit.

Timeframe: Approximately 28 days.

Trial details

NCT IDNCT01634087

SponsorIncyte Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-01

View on ClinicalTrials.gov More Plaque Psoriasis trials